207 related articles for article (PubMed ID: 30483269)
1. HVEM and CD160: Regulators of Immunopathology During Malaria Blood-Stage.
Muscate F; Stetter N; Schramm C; Schulze Zur Wiesch J; Bosurgi L; Jacobs T
Front Immunol; 2018; 9():2611. PubMed ID: 30483269
[TBL] [Abstract][Full Text] [Related]
2. CD160 isoforms and regulation of CD4 and CD8 T-cell responses.
El-Far M; Pellerin C; Pilote L; Fortin JF; Lessard IA; Peretz Y; Wardrop E; Salois P; Bethell RC; Cordingley MG; Kukolj G
J Transl Med; 2014 Sep; 12():217. PubMed ID: 25179432
[TBL] [Abstract][Full Text] [Related]
3. The impact of CD160 deficiency on alloreactive CD8 T cell responses and allograft rejection.
Del Rio ML; Nguyen TH; Tesson L; Heslan JM; Gutierrez-Adan A; Fernandez-Gonzalez R; Gutierrez-Arroyo J; Buhler L; Pérez-Simón JA; Anegon I; Rodriguez-Barbosa JI
Transl Res; 2022 Jan; 239():103-123. PubMed ID: 34461306
[TBL] [Abstract][Full Text] [Related]
4. CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator.
Cai G; Anumanthan A; Brown JA; Greenfield EA; Zhu B; Freeman GJ
Nat Immunol; 2008 Feb; 9(2):176-85. PubMed ID: 18193050
[TBL] [Abstract][Full Text] [Related]
5. Molecular basis for herpesvirus entry mediator recognition by the human immune inhibitory receptor CD160 and its relationship to the cosignaling molecules BTLA and LIGHT.
Kojima R; Kajikawa M; Shiroishi M; Kuroki K; Maenaka K
J Mol Biol; 2011 Nov; 413(4):762-72. PubMed ID: 21959263
[TBL] [Abstract][Full Text] [Related]
6. CD160 activation by herpesvirus entry mediator augments inflammatory cytokine production and cytolytic function by NK cells.
Šedý JR; Bjordahl RL; Bekiaris V; Macauley MG; Ware BC; Norris PS; Lurain NS; Benedict CA; Ware CF
J Immunol; 2013 Jul; 191(2):828-36. PubMed ID: 23761635
[TBL] [Abstract][Full Text] [Related]
7. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation.
Cai G; Freeman GJ
Immunol Rev; 2009 May; 229(1):244-58. PubMed ID: 19426226
[TBL] [Abstract][Full Text] [Related]
8. Modulation of cytotoxic responses by targeting CD160 prolongs skin graft survival across major histocompatibility class I barrier.
Del Rio ML; Bravo Moral AM; Fernandez-Renedo C; Buhler L; Perez-Simon JA; Chaloin O; Alvarez Nogal R; Fernandez-Caso M; Rodriguez-Barbosa JI
Transl Res; 2017 Mar; 181():83-95.e3. PubMed ID: 27702550
[TBL] [Abstract][Full Text] [Related]
9. Malaria-specific and nonspecific activation of CD8+ T cells during blood stage of Plasmodium berghei infection.
Miyakoda M; Kimura D; Yuda M; Chinzei Y; Shibata Y; Honma K; Yui K
J Immunol; 2008 Jul; 181(2):1420-8. PubMed ID: 18606696
[TBL] [Abstract][Full Text] [Related]
10. CD160 expression defines a uniquely exhausted subset of T lymphocytes in HTLV-1 infection.
Chibueze CE; Yoshimitsu M; Arima N
Biochem Biophys Res Commun; 2014 Oct; 453(3):379-84. PubMed ID: 25277889
[TBL] [Abstract][Full Text] [Related]
11. Role of B and T Lymphocyte Attenuator in Renal Transplant Recipients with Biopsy-Proven Acute Rejection.
Wang Z; Yang H; Liu X; Zhang J; Han Z; Tao J; Zhao C; Ju X; Tan R; Gu M
Med Sci Monit; 2018 Jan; 24():387-396. PubMed ID: 29352109
[TBL] [Abstract][Full Text] [Related]
12. Structural Basis of CD160:HVEM Recognition.
Liu W; Garrett SC; Fedorov EV; Ramagopal UA; Garforth SJ; Bonanno JB; Almo SC
Structure; 2019 Aug; 27(8):1286-1295.e4. PubMed ID: 31230945
[TBL] [Abstract][Full Text] [Related]
13. HVEM, a cosignaling molecular switch, and its interactions with BTLA, CD160 and LIGHT.
Rodriguez-Barbosa JI; Schneider P; Weigert A; Lee KM; Kim TJ; Perez-Simon JA; Del Rio ML
Cell Mol Immunol; 2019 Jul; 16(7):679-682. PubMed ID: 31160757
[No Abstract] [Full Text] [Related]
14. Expanded antigen-experienced CD160
Bozorgmehr N; Okoye I; Oyegbami O; Xu L; Fontaine A; Cox-Kennett N; Larratt LM; Hnatiuk M; Fagarasanu A; Brandwein J; Peters AC; Elahi S
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931471
[TBL] [Abstract][Full Text] [Related]
15. Sirolimus-based regimen promotes inhibitory costimulatory signal of HVEM/BTLA/CD160/LIGHT pathway in allo-renal recipients.
Bai Y; Shi Y; Li Y; Cai B; Zou Y; Wang L
Transpl Immunol; 2013 Jan; 28(1):38-47. PubMed ID: 23165214
[TBL] [Abstract][Full Text] [Related]
16. CD160 expression on CD8
Liu S; Zhang W; Liu K; Wang Y
Cancer Immunol Immunother; 2020 May; 69(5):789-797. PubMed ID: 32055919
[TBL] [Abstract][Full Text] [Related]
17. Memory CD8
Shaw TN; Haley MJ; Dookie RS; Godfrey JJ; Cheeseman AJ; Strangward P; Zeef LAH; Villegas-Mendez A; Couper KN
Immunology; 2021 Dec; 164(4):737-753. PubMed ID: 34407221
[TBL] [Abstract][Full Text] [Related]
18. BTLA interaction with HVEM expressed on CD8(+) T cells promotes survival and memory generation in response to a bacterial infection.
Steinberg MW; Huang Y; Wang-Zhu Y; Ware CF; Cheroutre H; Kronenberg M
PLoS One; 2013; 8(10):e77992. PubMed ID: 24205057
[TBL] [Abstract][Full Text] [Related]
19. Ligation of B and T lymphocyte attenuator prevents the genesis of experimental cerebral malaria.
Lepenies B; Pfeffer K; Hurchla MA; Murphy TL; Murphy KM; Oetzel J; Fleischer B; Jacobs T
J Immunol; 2007 Sep; 179(6):4093-100. PubMed ID: 17785848
[TBL] [Abstract][Full Text] [Related]
20. Targeting Angiotensin II Type-1 Receptor (AT
Silva-Filho JL; Caruso-Neves C; Pinheiro AA
Front Cell Infect Microbiol; 2017; 7():42. PubMed ID: 28261571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
